Our CEO Delivers Speech on Antibody R&D

As one of annual biopharmaceutical conference, the 8^th BioCon China 2021 was held on April 22 - 23 in Shanghai China. JECHO, the market player focusing on biopharmaceuticals’ innovations participated in the conference and engages in sessions. Our CEO, Dr. Jianwei Zhu was invited to address in topic speech, sharing his insights on Bispecific Antibody R&D.

Dr. Jianwei Zhu currently doubles as Director of Engineering Research Center of Cell Engineering and Antibody Drugs of Ministry of Education, and held the post of principal of School of Pharmacy, Shanghai Jiao Tong University earlier from April 2015 to July 2020. He provided a detailed interpretation of the Intein-mediated bispecific antibody manufacturing platform and its application in coronavirus antibodies, including advantages of high-fulx, mismatch reduction and simple purification. The Bispecific Antibody will achieve affinity improvement and has strong biological functions.

BioCon is hosted by Chinese Society of Biotechnology and “Biomap Global”, co-organized and supported by Chinese Biopharmaceutical Association-USA and other organizations.

For more information, please visit BioCon website: http://www.bmapglobal.com/biocon2021